-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Benzinga·09/23/2026 12:37:28
Listen to the news
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.